2013 Apr 15 Annual Report 2012 - Phosphagenics

More documents

Recommendations

Info

Notes to the consolidated fi nancial statements (ii) Accounting Standards and Interpretations issued but not yet effective Australian Accounting Standards and Interpretations that have recently been issued or amended but are not yet effective and have not been adopted by the Group for the annual reporting period ending 31 December 2012, outlined in the table below: Reference Title Summary AASB 2011-9 Amendments to Australian Accounting Standards - Presentation of Other Comprehensive Income [AASB 1, 5, 7, 101, 112, 120, 121, 132, 133, 134, 1039 & 1049] This standard requires entities to group items presented in other comprehensive income on the basis of whether they might be reclassifi ed subsequently to profi t or loss and those that will not. 70 AASB10 Consolidated Financial Statements AASB 10 establishes a new control model that applies to all entities. It replaces parts of AASB 127 Consolidated and Separate Financial Statements dealing with the accounting for consolidated fi nancial statements and UIG-112 Consolidation - Special Purpose Entities. The new control model broadens the situations when an entity is considered to be controlled by another entity and includes new guidance for applying the model to specifi c situations, including when acting as a manager may give control, the impact of potential voting rights and when holding less than a majority voting rights may give control. Consequential amendments were also made to other standards via AASB 2011-7. AASB 11 Joint Arrangements AASB 11 replaces AASB 131 Interests in Joint Ventures and UIG-113 Jointly-controlled Entities - Non-monetary Contributions by Ventures. AASB 11 uses the principle of control in AASB 10 to defi ne joint control, and therefore the determination of whether joint control exists may change. In addition it removes the option to account for jointly controlled entities (JCEs) using proportionate consolidation. Instead, accounting for a joint arrangement is dependent on the nature of the rights and obligations arising from the arrangement. Joint operations that give the venturers a right to the underlying assets and obligations themselves is accounted for by recognising the share of those assets and obligations. Joint ventures that give the venturers a right to the net assets is accounted for using the equity method. Consequential amendments were also made to other standards via AASB 2011-7 and amendments to AASB 128. PHOSPHAGENICS ANNUAL REPORT 2012
Application date of standard Impact on Group financial report Application date for Group 1 July 2012 These amendments result in changes to disclosures in the fi nancial statements and will have no impact on the fi nancial performance or position of the Group. 1 Jan 2013 1 Jan 2013 These amendments may have an impact on the Group; however the Group has not yet assessed the impact. 1 Jan 2013 71 1 January 2013 These amendments may have an impact on the Group; however the Group has not yet assessed the impact. 1 January 2013 NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
Page 1 and 2:
20 12 Annual Report PHOSPHAGENICS P
Page 3 and 4:
highlights March... April... May...
Page 5 and 6:
03 Jonathan Addison Chairman & Inde
Page 7 and 8:
COLLABORATIONS Strategic Collaborat
Page 9 and 10:
The Phosphagenics Evolution THE STO
Page 11 and 12:
“ We also reached agreement with
Page 13 and 14:
Overview of our opioid development
Page 15 and 16:
13 is branded as Butrans or Norspan
Page 17 and 18:
Personal Care ASHLAND INC (FORMERLY
Page 19 and 20:
BEAUTY IS MORE THAN SKIN DEEP 17 EL
Page 21 and 22: cellulite contour crème BioElixia
Page 23 and 24: Intellectual Property Title Countri
Page 25 and 26: 2009 2008 2007 2006 6.8 7.8 22.2 23
Page 27 and 28: DR ESRA OGRU (AGED 37 YEARS) BSC (H
Page 29 and 30: Senior Management DR PAUL GAVIN Chi
Page 31 and 32: Phosphagenics Limited ABN 32 056 48
Page 33 and 34: Directors’ Report Your directors
Page 35 and 36: Directors’ Report continued Looki
Page 37 and 38: Directors’ Report continued Commi
Page 39 and 40: Directors’ Report continued REMUN
Page 43 and 44: Directors’ Report continued Share
Page 45 and 46: Directors’ Report continued Share
Page 47 and 48: Exercise Price Expiry Date Net othe
Page 49 and 50: Exercise Price Expiry Date Net othe
Page 51 and 52: Fair value per performance right at
Page 55 and 56: Auditors Independence Declaration 5
Page 57 and 58: Corporate Governance Statement cont
Page 67 and 68: Consolidated statement of fi nancia
Page 69 and 70: Consolidated statement of changes i
Page 71: Notes to the consolidated fi nancia
Page 75 and 76: Application date of standard Impact
Page 81 and 82: Notes to the consolidated fi nancia
Page 113 and 114: Independent Auditor’s Report 111
Page 115 and 116: Additional Shareholder Information
Page 117 and 118: Additional Shareholder Information
Page 119: corporate directory Phosphagenics L
show all

2013 Apr 15 Annual Report 2012 - Phosphagenics

Create successful ePaper yourself

Delete template?

Save as template?